Related Experiment Video

Updated: Jul 8, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic

Anand Veeravagu1, Andrew R Hsu, Weibo Cai

  • 1Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305-5484, USA.

Recent Patents on Anti-Cancer Drug Discovery
|January 29, 2008
PubMed

Insights

Targeting vascular endothelial growth factor (VEGF) and its receptors inhibits tumor growth and metastasis. Anti-VEGF therapies show promise in increasing patient survival and enabling combination treatments for cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Tumor growth, invasion, and metastasis rely on new blood vessel formation (angiogenesis).
  • Vascular Endothelial Growth Factor (VEGF) and its receptors are critical regulators of angiogenesis and tumor progression.
  • VEGF signaling promotes endothelial cell proliferation, migration, differentiation, and survival.

Purpose of the Study:

  • To review patents targeting the VEGF family (VEGF [A-F], PIGF) and their receptors (VEGFR- [1-3]).
  • To focus on anti-cancer therapeutics designed to inhibit tumor vascular formation via VEGF pathway inhibition.
  • To highlight the therapeutic potential of anti-VEGF strategies in oncology.

Main Methods:

  • Literature review of scientific publications and patent databases.
  • Analysis of patents related to VEGF ligands (VEGF [A-F], PIGF) and receptors (VEGFR- [1-3]).
  • Focus on therapeutic applications for anti-cancer treatment.

Main Results:

  • Identification of seven VEGF ligand variants and three VEGFRs.
  • Development of novel inhibitory compounds targeting the VEGF pathway.
  • Clinical trials demonstrate efficacy of anti-VEGF therapies in reducing tumor size, metastasis, and angiogenesis.

Conclusions:

  • Anti-VEGF therapies are effective in reducing tumor burden and improving patient survival.
  • Inhibition of the VEGF pathway offers potential for increased progression-free and overall survival.
  • VEGF pathway inhibitors hold promise for combinatorial therapies in cancer treatment.

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.